Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Immunology
Fator do impacto: 1.404 FI de cinco anos: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimir: 1040-8401
ISSN On-line: 2162-6472

Volumes:
Volume 40, 2020 Volume 39, 2019 Volume 38, 2018 Volume 37, 2017 Volume 36, 2016 Volume 35, 2015 Volume 34, 2014 Volume 33, 2013 Volume 32, 2012 Volume 31, 2011 Volume 30, 2010 Volume 29, 2009 Volume 28, 2008 Volume 27, 2007 Volume 26, 2006 Volume 25, 2005 Volume 24, 2004 Volume 23, 2003 Volume 22, 2002 Volume 21, 2001 Volume 20, 2000 Volume 19, 1999 Volume 18, 1998 Volume 17, 1997 Volume 16, 1996 Volume 15, 1995 Volume 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v21.i1-3.70
18 pages

The Potential of CpG Oligodeoxynucleotides as Mucosal Adjuvants

Risini D. Weeratna
Coley Pharmaceutical Group, Ottawa
Paul J. Payette
Coley Pharmaceutical Group, Ottawa; Loeb Health Research Institute, Ottawa; Faculties of Health Sciences and Medicine, University of Ottawa
Heather L. Davis
Coley Pharmaceutical Group, Ottawa; Loeb Health Research Institute, Ottawa; Faculties of Health Sciences and Medicine, University of Ottawa

RESUMO

The development of mucosal vaccines for humans has been hindered by the lack of safe yet effective mucosal adjuvants. Bacterial toxins are commonly used as adjuvants in animal models, but they are too toxic for use in humans. A novel class of adjuvant is CpG DNA, which contains unmethylated CpG dinucleotides in particular base contexts (CpG motifs). CpG DNA is most often coadministered with antigen in the form of synthetic oligodeoxynucleotides (CpG ODN), which are made with a nuclease-resistant phosphorothioate backbone. The vast majority of studies using CpG DNA as adjuvant have been with parenteral delivery; recently, however, mucosal immunization with CpG DNA as adjuvant has also been shown to induce both systemic (humoral and cellular) and mucosal antigen-specific immune responses. This review will highlight the recent uses of CpG DNA as an adjuvant at mucosal surfaces.


Articles with similar content:

Novel Strategies Using DNA for the Induction of Mucosal Immunity
Critical Reviews™ in Immunology, Vol.19, 1999, issue 4
Heather L. Davis, Michael J. McCluskie
Muller Glia in Retinal Innate Immunity: A Perspective on Their Roles in Endophthalmitis
Critical Reviews™ in Immunology, Vol.33, 2013, issue 2
Mamta Kanwar, Lindsay J. Miller, Ashok Kumar, Pawan K. Singh, Rajeev K. Pandey
Mucosal Immunization: A Review of Strategies and Challenges
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.31, 2014, issue 4
Mohan N. Rathi, Hinal Patel, Chetan Yewale, Ambikanandan Misra
DNA Motifs Suppressing TLR9 Responses
Critical Reviews™ in Immunology, Vol.26, 2006, issue 6
Angela Trieu, Tara L. Roberts, Matthew J. Sweet, Jasmyn A. Dunn, Katryn J. Stacey
Intracellular Pattern Recognition Receptors and Renal Ischemia
Critical Reviews™ in Immunology, Vol.31, 2011, issue 4
Dianne B. McKay